Influx Healthtech Limited Schedules Investor Conference Call on May 22, 2026 to Discuss FY26 Earnings

Influx Healthtech Limited has announced an investor conference call scheduled for Friday, May 22, 2026, at 4:00 PM IST. The call has been organised by Capital Bridge Advisors and is intended to discuss the company's audited financial results for H2FY26 and FY26, covering the financial year ended March 31, 2026. The intimation was filed with the National Stock Exchange of India under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was signed by Managing Director Munir Abdul Ganee Chandniwala on May 14, 2026.

Conference Call Details

The investor call will follow the board meeting scheduled for Wednesday, May 20, 2026. The key details of the conference call are summarised below:

Parameter:	Details
Date:	Friday, May 22, 2026
Time:	16:00 Hrs (IST)
Agenda:	H2FY26 and FY26 Earnings Update
Organiser:	Capital Bridge Advisors

Management Representatives

The following senior management members from Influx Healthtech Limited will participate in the call:

Dr. Munir Chandniwala – MD & Chairman
Mr. Ashish Shah – Chief Financial Officer

Dial-In Details

Participants can join the conference call using the following dial-in numbers:

Region:	Details
Universal Dial-in (Primary):	+91 22 6280 1425
Universal Dial-in (Primary):	+91 22 7115 8802
International Toll-Free – USA:	1-866-746-2133
International Toll-Free – Hong Kong:	800 964 448
International Toll-Free – UK:	0808 101 1573
International Toll-Free – Singapore:	800 101 2045

Influx Healthtech Limited is headquartered at 109, Ghanshyam Enclave, Link Road, Laljipada, Kandivali (W), Mumbai – 400067, with its manufacturing facility located at Plot No. 9, 10, Phase II, Genesis Ind. Estate, Kolgaon, Palghar – 401 404, Maharashtra. The company can be reached via email at influxhealthtech@gmail.com or influxhealthcare1@gmail.com , and its website is www.influxhealthtech.com .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+9.77%	+2.78%	+28.23%	+46.68%	+130.19%	+130.19%

Influx Healthtech has successfully passed a Good Manufacturing Practices (GMP) inspection conducted by the Tanzania Bureau of Standards at their manufacturing facility. This significant milestone demonstrates the company's adherence to international quality standards and regulatory compliance requirements.

GMP Inspection Results

The Tanzania Bureau of Standards conducted a comprehensive inspection of the company's manufacturing facility and confirmed that it meets all required GMP standards. This certification is crucial for pharmaceutical and healthcare companies as it validates their manufacturing processes, quality control systems, and overall operational excellence.

Inspection Details:	Information
Regulatory Body:	Tanzania Bureau of Standards
Inspection Type:	Good Manufacturing Practices (GMP)
Result:	Successfully Passed
Facility Status:	Meets GMP Standards

Significance of GMP Compliance

Good Manufacturing Practices represent a system of guidelines that ensure products are consistently produced and controlled according to quality standards. The successful completion of this inspection indicates that Influx Healthtech's facility maintains:

Proper manufacturing processes and procedures
Adequate quality control measures
Compliance with international regulatory standards
Systematic approach to product quality assurance

Market Impact

This GMP certification enhances the company's credibility in international markets and strengthens its position in the healthcare sector. The approval from Tanzania Bureau of Standards validates the company's manufacturing capabilities and opens opportunities for expanded operations in the East African region.

The successful inspection outcome reflects Influx Healthtech's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its operations.